(+) BioLineRx shares rise over 11% on drug results (Proactiveinvestors) - Oct 9, 2012 - Shares of BioLineRx rose 11.22% to reach $3.37 apiece on Tuesday afternoon after the company released results from a P2b trial for its drug to treat patients with schizophrenia revealed improved cognitive functions
Stock price • Schizophrenia
|
|
BioLineRx Ltd (NASDAQ:BLRX) said results from a Phase IIb trial for its drug to treat patients with schizophrenia revealed improved cognitive functions.
Shares of the drug development company rose 11.22 per cent to reach $3.37 apiece on the Nasdaq on Tuesday afternoon.
The drug known as BL-1020, which is taken orally, showed it was significantly better than a placebo and similar to Risperidone, when compared to the Positive and negative Syndrome Scale and Clinical Global Impression scores.
The findings relate to results of the Phase IIb Eagle study that determined safety, efficacy as well as tolerability of the drug, compared to Risperidone – an atypical anti-psychotic drug...
|